Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;33(12):E7-12.
doi: 10.1002/clc.20634.

Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction

Affiliations

Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction

Li Dong-bao et al. Clin Cardiol. 2010 Dec.

Abstract

Objective: Angiographic slow/no-reflow during emergency percutaneous coronary intervention (PCI) in patients with ST-elevated acute myocardial infarction (AMI) may result in unfavorable outcomes. The aim of our study was to investigate the clinical factors and angiographic findings that predict slow/no-reflow phenomenon and the long-term prognosis of AMI patients with angiographic slow/no-reflow.

Methods: A total of 210 consecutive AMI patients, who underwent primary PCI within 12 hours of symptom onset were divided into a normal flow group (thrombolysis in myocardial infarction [TIMI] flow grade 3, n = 169) and a slow/no-reflow group (≤TIMI flow grade 2, n = 41), based on cineangiograms performed during PCI.

Results: A total of 41 patients (19.5%) developed slow/no-reflow phenomenon. Univariate analysis showed that delayed reperfusion, high thrombus burden on baseline angiography, and acute hyperglycemia all correlated with slow/no-reflow (P < 0.05 for all). Multivariate analysis revealed that hyperglycemia on admission (≥10 mmol/L; odds ratio [OR]: 1.7, 95% confidence interval [CI]: 1.423-2.971, P = 0.012), reperfusion time (≥6 h; OR:1.4, 95% CI: 1.193-1.695, P = 0.040), and high thrombus burden (OR: 1.6, 95% CI: 1.026-2.825, P = 0.031) were significant and independent predictors of angiographic slow/no-reflow. The 6-month mortality and incidence of major adverse cardiac and cerebrovascular events (MACCE) were significantly higher in the slow/no-reflow group than in the normal flow group. Angiographic slow/no-reflow was independently predictive of MACCE (hazard ratio [HR]: 2.642, 95% CI: 1.304-5.932, P = 0.028).

Conclusion: Delayed reperfusion, high thrombus burden on baseline angiography, and blood glucose level on admission can be used to stratify AMI patients into a lower or higher risk for angiographic slow/no-reflow during PCI. In addition, angiographic slow/no-reflow predicts an adverse outcome in AMI patients.

PubMed Disclaimer

References

    1. Weawer WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093–2098. - PubMed
    1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20. - PubMed
    1. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341: 1949–1956. - PubMed
    1. Morishima I, Sone T, Okumura K, et al. Angiographic no‐reflow phenomenon as a predictor of adverse long‐term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202–1209. - PubMed
    1. Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005; 150: 814–820. - PubMed

MeSH terms